Jefferies turned bullish on Summit Therapeutics Inc (SMMT), upgrading the stock to Buy and assigning a $25 price target, representing potential upside of 42.53% from Wednesday's close.
UGI Corp (UGI) has won the favor of Jefferies' equity research team. The firm upgraded the shares from Hold to Buy and moved its price target to $43, suggesting 11.57% additional upside for the stock.
Thermo Fisher Scientific Inc (TMO) received an upgrade from analysts at UBS, who also set their one-year price target on the stock to $730. They changed their rating on TMO to Buy from Neutral in a recently issued research note.
Wells Fargo reduced its rating on Amrize AG (AMRZ) stock to Equal Weight from Overweight and assigned the price target to $44.
JP Morgan analysts reduced their investment ratings, saying in research reports covered by the media that its rating for Dyne Therapeutics, Inc (DYN) has been changed to Underweight from Neutral and the new price target is set at $10.
Analysts at BofA Securities downgraded Patria Investments Ltd (PAX) stock to Underperform from Neutral, and the new price target is set at $10.